Download - Leukoplakia Treatment
![Page 1: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/1.jpg)
GOOD Afternoon
![Page 2: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/2.jpg)
Treatment of leukoplakia
![Page 3: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/3.jpg)
Leukoplakia: Treatment Options cessation of tobacco use/observation Chemoprevention Green tea Black tea retinoids vitamins (A,C,E) Carotenoids Bleomycin Fenretinide 5-fluorouracil photodynamic therapy surgical excision with or without grafting Cryosurgery( liquid nitrogen) laser ablation : CO2 antifungal (candida-associated leukoplakia)
![Page 4: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/4.jpg)
![Page 5: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/5.jpg)
GREEN TEA
• The most widely consumed beverages
• Second only to water
• Medicinal properties have been widely explored.
• Originates from China and has become associated with
many cultures in Asia from Japan to the Middle east.
•Available as kahwah
![Page 6: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/6.jpg)
The polyphenols found in tea are more commonly known
as flavanols or catechins
The main catechins are epicatechin, epicatechin-3-gallate,
epigallocatechin, and epigallocatechin-3-gallate (EGCG),
Have significant antioxidant, anticarcinogenic, anti-
inflammatory, thermogenic, probiotic, and antimicrobial
properties.
![Page 7: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/7.jpg)
Mechanism of action
Inhibition of tumor initiation and promotion, induction of apoptosis.
Inhibition of cell replication rates, In addition, green tea polyphenols stimulate the activity of
hepatic detoxification enzymes, thereby promoting detoxification of xenobiotic compounds.
![Page 8: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/8.jpg)
capable of chelating metal ions, such as iron, that can generate radical oxygen species.
inhibit the production of arachidonic acid metabolites such as pro inflammatory prostaglandins and leukotrienes, resulting in a decreased inflammatory response.
![Page 9: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/9.jpg)
The chemopreventive effect of green tea and its catechins on carcinogenesis have been attributed to their
inhibition on cell proliferation (Chen et al., 1998; Lea et al., 1993; Liang et al., 1999; Valcic et al., 1996),
cell cycle arrest (Liang et al., 1999), blockade of growth factor receptors (Fujiki et al., 1999;
Liang et al., 1977),
![Page 10: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/10.jpg)
suppression of mitotic signals (Lin et al., 1999). Reduction in cytokines release (Fujiki et al., 1999) Inhibition of angiogenesis by interfering with the activities of
metalloproteinases, serine proteinases and vascular endothelial growth factor (Jung et al., 2001).
![Page 11: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/11.jpg)
Black tea
Uses: Prevention of colon cancer Reduced incidence of oral mucosal leukoplakia Decreased recurrence of Stage I and II breast cancer Reduced risk and incidence of pancreatic cancer Squamous cell lung cancer Esophageal cancer
![Page 12: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/12.jpg)
contraindication
Individuals with weakened cardiovascular systems renal diseases thyroid hyperfunction elevated susceptibility to spasm certain psychic disorders (eg., panicky states of
anxiety)
![Page 13: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/13.jpg)
ADVERSE EFFECTS
Nervousness Anxiety Heart irregularities Headaches Tremors Hypertension Restlessness Insomnia Daytime irritability, Irritation of the gastric mucosa Diuresis.
![Page 14: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/14.jpg)
Black tea
Dose:150–250 ml boiling water poured over 2.5 g finely cut dried leaf
![Page 15: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/15.jpg)
Mechanism of action
Polyphenols may inhibit carcinogenesis by blocking endogenous formation of nitrosamines, polycyclic aromatic hydrocarbons, and heterocyclic amines (Bu-Abbas et al., 1994, 1995; Weisburger et al., 1994).
![Page 16: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/16.jpg)
Beta- carotene
Extremely Hydrophobic Molecules.
Found In Dark Green, Orange Or Yellowish Vegetables, Such As Spinach, Carrots, Sweet Potato, Mango, Papaya, And Oranges
Betacarotene Is A Vitamin A Precursor.
![Page 17: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/17.jpg)
recommended in order to prevent OL and possibly oral cancer
Antioxidizing action .
Ligation between beta-carotene and oxygen, which is an
unstable reactive molecule, thus diminishing the damaging
effects of free radicals
![Page 18: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/18.jpg)
Liede et al.
A diet supplemented with betacarotene can prevent changes
in the oral mucosa, especially in smoker patients, who present
low serum levels of vitamin C and beta-carotene when
compared to nonsmokers.
![Page 19: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/19.jpg)
Sankaranarayanan et al.
one third of patients (15 out of 46) that used 360 mg beta-
carotene per week during 12 months presented a complete
resolution of OL.
In the evaluative sessions one year after the treatment, 8 out
of 15 (54%) of the patients who had a complete response
presented recurrence
![Page 20: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/20.jpg)
Moreover, 12 months after stopping the supplements, 5% (2
out of 15) of the patients who had made use of beta-carotene
developed malignant neoplasia adjacent to the OL.
Side effects : In 5 patients, being 3 with headaches and 2
developed muscular pain
![Page 21: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/21.jpg)
In another study, 23 patients with OL were treated with beta-
carotene, in oral doses of 90mg/day, for three cycles of 3
months each. Of 18 patients who completed the study, 6
(33.3%) showed complete clinical response.
No significant clinical signs of toxicity were detected in any
of the patients
![Page 22: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/22.jpg)
Garewal et al. evaluated 50 patients with OL, treated with
beta-carotene at a dose of 60 mg/day, for six months. Only 2
patients (4%) demonstrated a complete clinical response.
![Page 23: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/23.jpg)
Lycopene
A Carotenoid without Provitamin A action.
Fat-soluble red pigment
Source : Tomatoes
![Page 24: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/24.jpg)
A positive relation between lycopene consumption and
cancer , cardiovascular diseases .
Has the uncommon feature of becoming bound to chemical
species that react to oxygen, thus being the most efficient
biological antioxidizing agent
![Page 25: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/25.jpg)
Has the capacity to modify intercellular exchange junctions,
and this is considered to be an anticancer mechanism .
![Page 26: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/26.jpg)
Singh et al. assessed the efficiency of lycopene in 58 cases of
OL.
The patients were divided into three groups, and received
8mg/day, 4mg/day, and placebo for a period of three months.
The supplementation of lycopene (8 mg/day and 4 mg/day)
reduced hyperkeratosis (clinically measured by the size of the
lesion) with a similar efficiency in 80% of the cases.
![Page 27: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/27.jpg)
The complete clinical response of patients receiving 8mg/day
was 55% and 4 mg/day was 25%, but this difference was not
statistically significant.
![Page 28: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/28.jpg)
VITAMINS
L-Ascorbic acid ( vitamin C)
Has antioxidizing properties and reacts with superoxide
produced as a result of the cells’ normal metabolic processes;
this inactivation of superoxide inhibits the formation of
nitrosamines during protein digestion and helps avoid damage
to DNA and cellular proteins.
![Page 29: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/29.jpg)
T.J. Bharth OL patients were treated with an association of beta-carotene,
vitamin E, and L-AA.
In 97.5% of patients, dysplasias were diminshed by use of
antioxidant combinations.
The reversion of the oral mucosa dysplastic changes was
more evident in the patients using antioxidative vitamins that
stopped smoking and ingestion of alcohol.
![Page 30: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/30.jpg)
There are no studies regarding the efficacy of the use of L-AA
alone for OL treatment.
![Page 31: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/31.jpg)
α-Tocoferol (AT) Vitamin E
Is the commonest and most active form of vitamin E.
Found in plant oil, margarine, and green leaves.
Tocoferol is an effective antioxidant at high levels of oxygen,
protecting cellular membranes from lipidic peroxidation
![Page 32: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/32.jpg)
Benner et al. evaluated the toxicity and efficacy of AT in 43
patients with OL in use of 400 IU twice daily for 24 weeks.
Follow-up was performed at 6, 12, and 24 weeks after the
beginning of treatment to assess toxicity, clinical response,
and serum AT levels.
![Page 33: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/33.jpg)
It was observed that 10 patients (23%) had complete clinical
remission of lesion and 10 (23%) had a partial clinical
response. Nine (21%) had histologic responses (complete
reversal of dysplasia to normal epithelium).
Mean serum AT levels were 16.1 μg/mL at baseline and
increased to 34.29 μg/mL after 24 weeks of treatment.
![Page 34: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/34.jpg)
Retinoic acid ( vitamin A)
Supplementation with retinoids for OL treatment began in the
1960s.
However, this treatment was not widely accepted due to its
side effects—Hypervitaminosis, Toxicity, Teratogenic effects,
and alterations in various organic systems
![Page 35: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/35.jpg)
At the cellular-level, retinoids interact with surface receptors
and penetrate the cell. They are subsequently metabolized and
transported to the nucleus by various proteins.
![Page 36: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/36.jpg)
Retinoids affect diverse processes, such as keratin production
the expression of growth factors and kinases, apoptosis,
production of the collagen matrix, immunologic and
inflammatory response, cellular differentiation, and
carcinogenesis
![Page 37: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/37.jpg)
However, the high recurrence rates after short periods of
discontinuance, together with its side effects, are limiting
factors
![Page 38: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/38.jpg)
Kaugars et al. implemented retinoic supplementation in various dosages for OL treatment.
Fifty percent of patients had complete or partial clinical resolution of OL, but with side effects such as dizziness and headache.
OL recurred upon the discontinuance of medication. Some patients ceased treatment due to its side-effects.
![Page 39: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/39.jpg)
On the other hand, during the assessment of 13-cRA topical
use (0.1% isotretinoin gel) for 4 months, in 9 patients with
OL, 20% showed complete clinical response to treatment and
no patient reported adverse effects.
![Page 40: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/40.jpg)
Toma et al.
sixteen patients
The initial dose, given for 3 months, was 0.2 mg/kg/day,
increasing by a further 0.2 mg/kg/day in successive 3 month
cycles
![Page 41: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/41.jpg)
The maximum dosage reached 1.0mg/kg/day.
Fourteen of the patients completed the trial and there was one
complete response obtained at 0.4 mg/kg/day. After the
retinoic acid treatment was stopped, patients were followed-
up for 12 months; 2 patients showed regression of the
responses obtained after 6 and 9 months
![Page 42: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/42.jpg)
In the systemic use with dosage of 300.000 IU of retinoic acid
(Vitamin A): A clinical resolution of the 50%
In topical use with dosage range from 0.05% to 1% : a
clinical resolution from 10% to 27%
![Page 43: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/43.jpg)
SIDE EFFECTS
Retinoid associated increases in serum cholesterol and triglyceride levels
Cheilitis Zerosis and conjunctivitis There is no proven and generally safe retinoid currently free
of undesirable side-effects.
![Page 44: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/44.jpg)
Response rates of leukoplakias and reduction of
transformation to primary squamous cell carcinomas by 13-
cis-retinoic acid have been noted
(Huber and Hong, 1994; Toma et al, 1994).
![Page 45: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/45.jpg)
Fenretinide. Fenretinide (4-HPR) or N-(4-hydroxyphenyl)
A characteristic feature of 4-HPR is its ability to inhibit cell
growth through the induction of apoptosis with mechanisms
that may be both receptor-dependent and receptor-
independent.
Chemopreventive efficacy of fenretinide has been
investigated in clinical trials targeted at different organs
![Page 46: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/46.jpg)
Tradati et al
Systemic use of 4-HPR with 200 mg/day for 3 months in 35
patients demonstrated partial clinical resolution of OL of 12
patients
![Page 47: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/47.jpg)
Topical bleomycin
Topical bleomycin in treatment of OL was used in dosages of
0.5%/day for 12 to 15 days or 1%/day for 14 days
![Page 48: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/48.jpg)
Topical application of bleomycin ( Malmstrom et al 1988; Wong et al 1989)
Slower recurrence
![Page 49: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/49.jpg)
Available as: Efudex Fluoroplex 5-FU
5 Fluorouracil
![Page 50: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/50.jpg)
indication
Actinic keratoses Actinic cheilitis Leukoplakia Radiodermatitis Bowen's disease Erythroplasia of Queyrat basal cell carcinomas
![Page 51: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/51.jpg)
Mechanism of action
Interferes with the synthesis of DNA.
Inhibits the formation of RNA.
Since DNA and RNA are essential for cell division and growth, the effect of fluorouracil may be to create a thymine deficiency, which provokes unbalanced growth and death of the cell
![Page 52: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/52.jpg)
Adverse effects
Myelosuppression Mucositis Dermatitis diarrhea cardiac toxicity. acute CNS damage
![Page 53: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/53.jpg)
Photodynamic therapy
noninvasive method principle : nonthermal photochemical reaction, which
requires the simultaneous presence of a photosensitising drug (photosensitiser), oxygen, and visible light. After a period to allow the photosensitiser to collect in the target tissue, the photosensitiser is activated by exposure to low-power visible light of a drug-specific wavelength.
![Page 54: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/54.jpg)
light source : a portable diode laser and the light is transmitted via laser fibres to or into the tumour. Illumination of the tumour by light at the activating wavelength results in the destruction of cells by a nonfree radical oxidative process.
![Page 55: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/55.jpg)
These reactive oxygen species may damage crucial cell components, such as structural proteins, enzymes, DNA, and phospholipids.
PDT damage heals mainly by regeneration rather than scarring. Due to the orga preserving principle of PDT, important structures are maintained with good functional and cosmetic outcome
![Page 56: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/56.jpg)
Advantages: Inactivation of clinically subtle or undetectable alteration sparing of normal tissue minimal morbidity
![Page 57: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/57.jpg)
Chen et al. Treated 24 patients with OL using 20% ALA-PDT, once a
week; another 24 patients used 20% ALA-PDT twice a week. In the latter group, 8 completely responded to the treatment, 16 partially responded, and 9 did not.
All patients from the twice-a-week group responded significantly better than those treated only once a week.
![Page 58: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/58.jpg)
Treatment: Homogenous Leukoplakia
Patient education & motivation Identification & removal of any predisposing
factors. Anti-fungal agents - 2 weeks may reduce lesion
size. Periodic observation. Increase in lesion size / change in appearance
indicates need for histological examination. Dysplastic changes indicate surgical removal and
long term follow-up.
![Page 59: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/59.jpg)
Treatment: Speckled /Verrucous Leukoplakia
Patient education & motivation Identification and removal of any predisposing
factors. Histological examination. Dysplastic changes indicate surgical removal and
long term follow-up. Non-dysplastic lesions may be treated similar to
homogenous variety.
![Page 60: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/60.jpg)
In the absence of histologically demonstrated dysplastic changes , and routine follow up observation of leukoplakia with elimination of any risk associated behavior or habit.
The patient is followed every 4 months for the first 2 years which is extended for 6 months if the lesion is stable.
![Page 61: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/61.jpg)
Dysplastic lesion
SURGICAL EXCISION Scalpel Cryosurgery Electrocautery Laser Ablation Photodynamic Therapy Radiotherapy : 5,000 CGy to 6,500 CGy
![Page 62: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/62.jpg)
References Text book of oral pathology Shafer’s Hine Levy 5th edition Oral & maxillofacial pathology Neville Damm Allen Bouquot 2nd edition. Tobacco-related oral mucosal lesion and conditions in India: A guide for
dental students, Dentists, and Physician, Fali S. Mehta James E.Hamner. Oral cancer Jatin P Shah, Newell W Johnson, John G Batsakis Robbins Pathologic basis of diseases, Cortran, Kumar Robbins 5th. Oral leukoplakia, critical Review Oral Biol Med 1995,6,(2):147-160. Advanced methods in the evaluation of premalinant lesions and carcinomas
of oral mucosa, journal of oral pathology 1985: 14, 751-778 Mirian Aparecida Onofre, Maria Regina Sposto, Claudia Maria Navarro.
Reliability of toludine blue application in the detection of oral epithelial dysplasia ad in situ invasive sqamous cell carcinomas( Oral Surg Oral Med Oral Pathol Oral Radiol Endod2001;91:535-540.
Mahesh Chandra Hegde, Panduranga M. Kamath, Suja Shreedharan, Naveen Kumar, Ravikumar M. Raju Indian Journal of Otolaryngology and Head And Neck Surgery Vol.58, No.1, Jan-march 2006.
![Page 63: Leukoplakia Treatment](https://reader035.vdocuments.us/reader035/viewer/2022062404/55255d5e550346586f8b47c7/html5/thumbnails/63.jpg)
Harbans Lal, rajesh pandey and S.K. Agarwak, antioxidant vitamins and chemoprevention: indian journal of clinical biochemistry 1999, 14:1, 1-11.
Adriana spinola ribeiro et al: a review of the nonsurgical treatment of oral leukoplakia, international journal of dentistry 2009
Axell T, Pindborg JJ, Smith CJ, van der Waal I. Oral white lesions with special reference to precancerous and tobacco related lesions: conclusions of an international symposium held in Uppsala, Sweden, May 18—21 1994. International Collaborative Group on Oral White Lesions. J Oral Pathol Med 1996; 25(2):49—54